Adoram Therapeutics Secures CHF 1 Million Grant from Innosuisse
Share this article
Adoram Therapeutics has secured a CHF 1.05 million grant from Innosuisse to propel its groundbreaking anti-inflammatory programme, aiming to develop safer and more effective therapies.
Adoram Therapeutics is a University of Geneva (UNIGE) spinoff specializing in allosteric modulators for cancer immunotherapy and inflammatory conditions.
The Innosuisse Grant will allow the research will be conducted in collaboration with the groups of Professors Leonardo Scapozza and Cem Gabay of the University of Geneva. The work done in the laboratory of Professor Leonardo Scapozza, a distinguished expert in drug discovery, has laid the scientific groundwork that enabled this milestone. His laboratory’s previous collaboration with Adoram Therapeutics was instrumental in shaping the research direction, providing the strong foundation upon which this grant was secured. His expertise in molecular pharmacology and innovative drug design has been vital to advancing the program toward clinical application.
Professor Cem Gabay, a leading authority in autoimmunity and inflammation biology, has dedicated his career to advancing the understanding of inflammatory diseases and pioneering innovative therapeutic approaches. His deep expertise at the translational and clinical level in cytokine signalling and inflammation-related pathologies positions him as a driving force in developing transformative treatments.
“This grant validates the impactful collaboration between our team and Professors Scapozza and Gabay, whose combined expertise has been instrumental in reaching this milestone,” said David PEJOSKI, co-CEO/COO of Adoram Therapeutics.
“We are proud to continue working alongside them to advance therapies for inflammation-related diseases and are deeply grateful to Innosuisse for their support.” “With this funding, Adoram Therapeutics is set to accelerate its eƯorts in nominating a promising development candidate and delivering groundbreaking therapies to patients suƯering from inflammation-driven conditions” said Hesham HAMED, Co-CEO and CSO of Adoram Therapeutics.
➡️ Source: Adoram Therapeutics | 📸 Adoram Therapeutics’ team. © Adoram Therapeutics